Abstract
Cystic fibrosis (CF) is the most common autosomal recessive genetic disorder in the Caucasian population, with 1 out of every 2000 live births affected by this disease (1,2). The symptoms of CF appear in early childhood, and although the duration of the disease depends strongly on the severity of symptoms and availability of treatment options, it generally becomes fatal by the age of 30–40. The hallmark of the disease is the abnormal viscosity of mucous secretions resulting from the altered electrolyte transport across epithelial cell membranes. CF symptoms include pancreatic and gastrointestinal (GI) insufficiency, recurring lung infections, obstruction of sinuses, and male infertility. These pleiotropic symptoms arise as a result of mutations in a single gene, termed cystic fibrosis transmembrane conductance regulator (CFTR) (3–5). Understanding the mechanisms of biogenesis, folding, and degradation of the CFTR gene product is crucial for unraveling the molecular basis of CF pathogenesis, and will be the focus of this chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tsui, L. C., Rommens, J., Kerem, B., Rozmahel, R., Zielenski, J., Kennedy, D., et al. (1991) Molecular genetics of cystic fibrosis. Adv. Exp. Med. Biol. 290, 9–17; discussion 17–18.
Jaffe, A., and Bush, A. (2001) Cystic fibrosis: review of the decade. Monaldi Arch. Chest. Dis. 56, 240–247.
Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066–1073.
Rommens, J. M., Dho, S., Bear, C. E., Kartner, N., Kennedy, D., Riordan, J. R., et al. (1991) cAMP—inducible chloride conductance in mouse fibroblast lines stably expressing the human cystic fibrosis transmembrane conductance regulator. Proc. Natl. Acad. Sci. USA 88, 7500–7504.
Kerem, E. and Kerem, B. (1995) The relationship between genotype and phenotype in cystic fibrosis. Curr. Opin. Pulm. Med. 1, 450–456.
Gadsby, D. C. and Nairn, A. C. (1999) Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Physiol. Rev. 79, S77–S107.
Puchelle, E., Gaillard, D., Ploton, D., Hinnrasky, J., Fuchey, C., Boutterin, M. C., et al. (1992) Differential localization of the cystic fibrosis transmembrane conductance regulator in normal and cystic fibrosis airway epithelium. Am. J. Respir. Cell Mol. Biol. 7, 485–491.
Bannykh, S. I., Bannykh, G. I., Fish, K. N., Moyer, B. D., Riordan, J. R., and Balch, W. E. (2000) Traffic pattern of cystic fibrosis transmembrane regulator through the early exocytic pathway. Traffic 1, 852–870.
Kalin, N., Claass, A., Sommer, M., Puchelle, E., and Tummler, B. (1999) DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis. J. Clin. Invest. 103, 1379–1389.
Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., et al. (1990) Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63, 827–834.
Lukacs, G. L., Mohamed, A., Kartner, N., Chang, X. B., Riordan, J. R., and Grinstein, S. (1994) Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J. 13, 6076–6086.
Ward, C. L. and Kopito, R. R. (1994) Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J. Biol. Chem. 269, 25,710–25,718.
Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E. and Welsh, M. J. (1992) Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358, 761–764.
Drumm, M. L., Wilkinson, D. J., Smit, L. S., Worrell, R. T., Strong, T. V., Frizzell, R. A., et al. (1991) Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science 254, 1797–1799.
Yang, Y., Janich, S., Cohn, J. A., and Wilson, J. M. (1993) The common variant of cystic fibrosis transmembrane conductance regulator is recognized by Hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc. Natl. Acad. Sci. USA 90, 9480–9484.
Pind, S., Riordan, J. R., and Williams, D. B. (1994) Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 269, 12,784–12,788.
Loo, M. A., Jensen, T. J., Cui, L., Hou, Y., Chang, X. B., and Riordan, J. R. (1998) Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. EMBO J. 17, 6879–6887.
Meacham, G. C., Lu, Z., King, S., Sorscher, E., Tousson, A., and Cyr, D. M. (1999) The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. EMBO J. 18, 1492–1505.
Meacham, G. C., Patterson, C., Zhang, W., Younger, J. M., and Cyr, D. M. (2001) The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat. Cell Biol. 3, 100–105.
Qu, B. H., Strickland, E. H., and Thomas, P. J. (1997) Localization and suppression of a kinetic defect in cystic fibrosis transmembrane conductance regulator folding. J. Biol. Chem. 272, 15,739–15,744.
Zhang, F., Kartner, N., and Lukacs, G. L. (1998) Limited proteolysis as a probe for arrested conformational maturation of delta F508 CFTR. Nat. Struct. Biol. 5, 180–183.
Pasyk, E. A. and Foskett, J. K. (1995) Mutant (delta F508) cystic fibrosis transmembrane conductance regulator Cl-channel is functional when retained in endoplasmic reticulum of mammalian cells. J. Biol. Chem. 270, 12,347–12,350.
Choo-Kang, L. R. and Zeitlin, P. L. (2000) Type I, II, III, IV, and V cystic fibrosis transmembrane conductance regulator defects and opportunities for therapy. Curr. Opin. Pulm. Med. 6, 521–529.
Ward, C. L., Omura, S., and Kopito, R. R. (1995) Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83, 121–127.
Jensen, T. J., Loo, M. A., Pind, S., Williams, D. B., Goldberg, A. L., and Riordan, J. R. (1995) Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83, 129–135.
Sato, S., Ward, C. L., and Kopito, R. R. (1998) Cotranslational ubiquitination of cystic fibrosis transmembrane conductance regulator in vitro. J. Biol. Chem. 273, 7189–7192.
Xiong, X., Chong, E., and Skach, W. R. (1999) Evidence that endoplasmic reticulum (ER)-associated degradation of cystic fibrosis transmembrane conductance regulator is linked to retrograde translocation from the ER membrane. J. Biol. Chem. 274, 2616–2624.
Oberdorf, J., Carlson, E. J., and Skach, W. R. (2001) Redundancy of mammalian proteasome beta subunit function during endoplasmic reticulum associated degradation. Biochemistry 40, 13,397–13,405.
Bebok, Z., Mazzochi, C., King, S. A., Hong, J. S., and Sorscher, E. J. (1998) The mechanism underlying cystic fibrosis transmembrane conductance regulator transport from the endoplasmic reticulum to the proteasome includes Sec61beta and a cytosolic, deglycosylated intermediary. J. Biol. Chem. 273, 29,873–29,878.
Johnston, J. A., Ward, C. L., and Kopito, R. R. (1998) Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 143, 1883–1898.
Gelman, M. S., Kannegaard, E. S., and Kopito, R. R. (2002) A principal role for the proteasome in ER-associated degradation of misfolded intracellular CFTR. J. Biol Chem. 77, 11,709–11,714.
Bordallo, J., Plemper, R. K., Finger, A., and Wolf, D. H. (1998) Der3p/Hrd1p is required for endoplasmic reticulum-associated degradation of misfolded lumenal and integral membrane proteins. Mol. Biol. Cell 9, 209–222.
Bays, N. W., Gardner, R. G., Seelig, L. P., Joazeiro, C. A., and Hampton, R. Y. (2001) Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-associated degradation. Nat. Cell Biol. 3, 24–29.
Swanson, R., Locher, M., and Hochstrasser, M. (2001) A conserved ubiquitin ligase of the nuclear envelope/endoplasmic reticulum that functions in both ER-associated and Matalpha2 repressor degradation. Genes Dev. 15, 2660–2674.
Sato, S., Ward, C. L., Krouse, M. E., Wine, J. J., and Kopito, R. R. (1996) Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem. 271, 635–638.
Brown, C. R., Hong-Brown, L. Q., and Welch, W. J. (1997) Correcting temperature-sensitive protein folding defects. J. Clin. Invest. 99, 1432–1444.
Brown, C. R., Hong-Brown, L. Q., Biwersi, J., Verkman, A. S., and Welch, W. J. (1996) Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1, 117–125.
Morello, J. P., Petaja-Repo, U. E., Bichet, D. G., and Bouvier, M. (2000) Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol. Sci. 21, 466–469.
Loo, T. W. and Clarke, D. M. (1997) Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. J. Biol. Chem. 272, 709–712.
Morello, J. P., Salahpour, A., Laperriere, A., Bernier, V., Arthus, M. F., Lonergan, M., et al. (2000) Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Invest. 105, 887–895.
Jiang, C., Fang, S. L., Xiao, Y. F., O’Connor, S. P., Nadler, S. G., Lee, D. W., et al. (1998) Partial restoration of cAMP-stimulated CFTR chloride channel activity in DeltaF508 cells by deoxyspergualin. Am. J. Physiol. 275, C171–C178.
Andersson, C. and Roomans, G. M. (2000) Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX. Eur. Respir. J. 15, 937–941.
Arispe, N., Ma, J., Jacobson, K. A., and Pollard, H. B. (1998) Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX). J. Biol. Chem. 273, 5727–5734.
Zeitlin, P. L. (2000) Pharmacologic restoration of delta F508 CFTR-mediated chloride current. Kidney Int. 57, 832–837.
Maitra, R., Shaw, C. M., Stanton, B. A., and Hamilton, J. W. (2001) Increased functional cell surface expression of CFTR and DeltaF508-CFTR by the anthracycline doxorubicin. Am. J. Physiol. Cell Physiol. 280, C1031–1037.
Dormer, R. L., Derand, R., McNeilly, C. M., Mettey, Y., Bulteau-Pignoux, L., Metaye, T., et al. (2001) Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. J. Cell Sci. 114, 4073–4081.
Heda, G. D. and Marino, C. R. (2000) Surface expression of the cystic fibrosis transmembrane conductance regulator mutant DeltaF508 is markedly upregulated by combination treatment with sodium butyrate and low temperature. Biochem. Biophys. Res. Commun. 271, 659–664.
Egan, M. E., Glockner-Pagel, J., Ambrose, C. A., Cahill, P. A., Pappoe, L., Balamuth, N., et al. (2002) Calcium-pump inhibitors induce functional surface expression of DeltaF508-CFTR protein in cystic fibrosis epithelial cells. Nat. Med. 8, 485–492.
Sharma, M., Benharouga, M., Hu, W., and Lukacs, G. L. (2001) Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments. J. Biol. Chem. 276, 8942–8950.
Heda, G. D., Tanwani, M., and Marino, C. R. (2001) The Delta F508 mutation shortens the biochemical half-life of plasma membrane CFTR in polarized epithelial cells. Am. J. Physiol. Cell Physiol. 280, C166–C174.
Galietta, L. V., Jayaraman, S., and Verkman, A. S. (2001) Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am. J. Physiol. Cell Physiol. 281, C1734–C1742.
Galietta, L. J., Springsteel, M. F., Eda, M., Niedzinski, E. J., By, K., Haddadin, M. J., et al. (2001) Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J. Biol. Chem. 276, 19,723–19,728.
Moyer, B. D., Loffing, J., Schwiebert, E. M., Loffing-Cueni, D., Halpin, P. A., Karlson, K. H., et al. (1998) Membrane trafficking of the cystic fibrosis gene product, cystic fibrosis transmembrane conductance regulator, tagged with green fluorescent protein in madin-darby canine kidney cells. J. Biol. Chem. 273, 21,759–21,768.
Howard, M., DuVall, M. D., Devor, D. C., Dong, J. Y., Henze, K., and Frizzell, R. A. (1995) Epitope tagging permits cell surface detection of functional CFTR. Am. J. Physiol. 269, C1565–C1576.
Schultz, B. D., Takahashi, A., Liu, C., Frizzell, R. A., and Howard, M. (1997) FLAG epitope positioned in an external loop preserves normal biophysical properties of CFTR. Am. J. Physiol. 273, C2080–C2089.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Gelman, M.S., Kopito, R.R. (2003). Cystic Fibrosis. In: Bross, P., Gregersen, N. (eds) Protein Misfolding and Disease. Methods in Molecular Biology™, vol 232. Humana Press. https://doi.org/10.1385/1-59259-394-1:27
Download citation
DOI: https://doi.org/10.1385/1-59259-394-1:27
Publisher Name: Humana Press
Print ISBN: 978-1-58829-065-6
Online ISBN: 978-1-59259-394-1
eBook Packages: Springer Protocols